Title: Methods for cytotoxic chemotherapy-based predictive assays

Abstract

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

Inventors:

Henderson, Paul; Cimino, George D.; Pan, Chong-xian; de Vere White, Ralph William; Zimmermann, Maike; Turteltaub, Kenneth W.

Issue Date:

2022-10-18

Research Org.:

Lawrence Livermore National Laboratory (LLNL), Livermore, CA (United States)

Sponsoring Org.:

USDOE Laboratory Directed Research and Development (LDRD) Program; National Institutes of Health (NIH)

OSTI Identifier:

1986713

Patent Number(s):

11474106

Application Number:

15/742,454

Assignee:

Lawrence Livermore National Security, LLC (Livermore, CA)

Patent Classifications (CPCs):

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

A61K2300/00 - Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K31/28 - Compounds containing heavy metals
A61K31/395 - having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/555 - containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K31/7068 - having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K33/24 - Heavy metals
A61K33/243 - Platinum

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P35/00 - Antineoplastic agents

G - PHYSICS G01 - MEASURING G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES

G01N2800/52 - Predicting or monitoring the response to treatment
G01N2800/56 - Staging of a disease
G01N33/5308 - {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
G01N33/57484 - {involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites}
G01N33/60 - involving radioactive labelled substances
G01N33/6848 - {Methods of protein analysis involving mass spectrometry}
G01N33/96 - involving blood or serum control standard

Show less

DOE Contract Number:  

LDRD 08-LW-100; 1K12CA138464-01A2; HEISN26120100013C; HEISN26120100048C; HEISN26120100084C; P41 RR13461

Resource Type:

Patent

Resource Relation:

Patent File Date: 07/07/2016

Country of Publication:

United States

Language:

English